UNSPSC 51372804: Eptazocine

This classification denotes an analgesic agent with the molecular formula C15H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2208ZLI77S, chemically known as 1,6-methano-1h-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1s)- but generally known as eptazocine, which bears US NIH Compound Identifier 3246. European Medicines Agency schedules Eptazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06594MIG. The term EPTAZOCINE is an International Non-Proprietary Name.

UNSPSC 51372804 Eptazocine, a Commodity code, shows limited recent activity directly aligned with its nominal scope; state and local governments posting under this code are actually procuring naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through various contracting mechanisms. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering agreements that include Oregon and other participating jurisdictions). Work being solicited includes procurement of naloxone and drug disposal systems for community health initiatives, requests for information on direct-to-manufacturer prescription programs, and framework agreements for generic pharmaceuticals and OTC products distributed through authorized wholesalers to state and local government facilities.

Recent opportunities span Florida, Texas, and Minnesota, with cooperative purchasing agreements extending across multiple states. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for direct-to-manufacturer prescription programs to inform future formal solicitation strategy. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, with a March 26, 2026, response deadline to establish multiple contracts for generic pharmaceuticals and OTC products; awarded vendors must maintain relationships with AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with resulting agreements effective July 1, 2026. Vendors must comply with cGMP certification, Drug Supply Chain Security Act requirements, E-Verify compliance, and specific insurance thresholds including $5 million commercial general liability.